Highbridge Capital Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Highbridge Capital Management’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-42,154	Closed	-$108K	–	601
2022 Q3	$108K	Sell	42,154 -118,266	-74%	-$294K	﹤0.01%	479
2022 Q2	$310K	Sell	160,420 -42,663	-21%	-$93.1K	0.01%	423
2022 Q1	$603K	Buy	+203,083	New	+$764K	0.01%	413
2017 Q4	–	Sell	-210,550	Closed	-$5.29M	–	2053
2017 Q3	$5.29M	Buy	+210,550	New	+$4.9M	0.08%	279
2017 Q2	–	Sell	-38,953	Closed	-$749K	–	1695
2017 Q1	$749K	Buy	+38,953	New	+$614K	0.01%	734
2016 Q4	–	Sell	-38,503	Closed	-$501K	–	1669
2016 Q3	$501K	Buy	+38,503	New	+$510K	0.01%	782

Other funds holding PRTK

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Highbridge Capital Management's PRTK Position: Q4 2022 in Review

Highbridge Capital Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q4 2022, closing a stake of 42,154 shares — an estimated $108K sold.

Highbridge Capital Management first reported a position in PRTK in Q3 2016 and held it in 6 quarters. The position peaked at $5.29M in Q3 2017. 76 funds tracked by Wall St. Rank hold PRTK as of Q4 2022.

Highbridge Capital Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
Highbridge Capital Management sold 42,154 Paratek Pharmaceuticals, Inc. shares in Q4 2022, an estimated $108K.
Highbridge Capital Management first reported a position in Paratek Pharmaceuticals, Inc. in Q3 2016 and held it in 6 quarters.
Highbridge Capital Management's Paratek Pharmaceuticals, Inc. position peaked at $5.29M in Q3 2017.
76 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2022.

Based on Highbridge Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.